多虑平联合马来酸曲美布汀治疗肠易激综合征临床疗效观察.docVIP

多虑平联合马来酸曲美布汀治疗肠易激综合征临床疗效观察 　　[摘要] 目的 观察及研究多虑平联合马来酸曲美布汀治疗肠易激综合征的临床疗效。方法 方便选取2014年2月―2015年4月于该院进行治疗的52例肠易激综合征患者为研究对象，将其遵照随机分配的原则分为对照组（常规肠易激综合征治疗组）26例和观察组（多虑平联合马来酸曲美布汀组）26例，然后将两组患者中轻中度及重度治疗总有效率、治疗前后的血清相关指标进行比较。 结果 观察组的轻中度及重度治疗总有效率分别为100.00%和92.31%，均高于对照组的76.92%和61.54%，治疗后2周及4周的血清SP、VIP、5-HT及SS水平分别为（2.15±0.24）ug/mL、（3.27±0.52）umol/L、（16.31±1.76）ng/mL、（101.57±9.21）pg/dL及（1.42±0.20）ug/mL、（2.08±0.30）umol/L、（13.22±1.45）ng/mL、（86.76±8.20）pg/dL，均低于对照组，P均0.05，差异有统计学意义。 结论 多虑平联合马来酸曲美布汀治疗肠易激综合征的临床疗效较好，对于疾病各方面的改善作用均更为明显。 　　[关键词] 多虑平；马来酸曲美布汀；肠易激综合征；临床疗效 　　[中图分类号] R737.33 [文献标识码] A [文章编号] 1674-0742（2016）05（a）-0116-03 　　[Abstract] Objective To observe and research the clinical curative effect of doxepin and trimebutine in treatment of irritable bowel syndrome. Methods 52 cases of patients with irritable bowel syndrome treated in our hospital from February 2014 to April 2015 were selected as the research objects and randomly divided into two groups with 26 cases in each， the control group were treated with conventional irritable bowel syndrome， the observation group were treated with doxepin and trimebutine， and then the total effective rates of mild， moderate and severe treatment and indexes related to serum before and after treatment of the two groups were compared. Results The total effective rates of mild， moderate and severe treatment in the observation group were higher than those in the control group （100.00%， 92.31% vs 76.92%， 61.54%）， the serum SP， VIP， 5-HT and SS levels in 2-week and 4-week after treatment were respectively （2.15±0.24） ug/mL、（3.27±0.52） umol/L， （16.31±1.76） ng/mL， （101.57±9.21） pg/dl and （1.42±0.20） ug/mL， （2.08±0.30） umol/L， （13.22±1.45） ng/mL， （86.76±8.20） pg/dl， which were lower than those in the control group， and all had obvious difference， all P0.05. Conclusion The clinical curative effect of doxepin and trimebutine in treatment of irritable bowel syndrome is better， and it is more obvious in improving various aspects of diseases. 　　[Key words]